Table 1.
Results from prospective and retrospective trials evaluating cessation of TKIs in CML
Results from prospective and retrospective trials evaluating cessation of TKIs in CML

IS indicates International Score; and Q-PCR, quantitative PCR.

*Previous stem cell transplantation was allowed in some patients.

†Assay sensitivity was not reported.

‡Second-generation TKIs, dasatinib and nilotinib after IM intolerance or suboptimal response to IM.

§This trial included 23 patients who had previously undergone an allogeneic stem cell transplant, 3 patients received second-generation TKIs for IM intolerance.

‖Some of these patients were included in the analysis of the Korean KIDS study as well.

or Create an Account

Close Modal
Close Modal